223 related articles for article (PubMed ID: 24186132)
21. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.
Myers KC; Furutani E; Weller E; Siegele B; Galvin A; Arsenault V; Alter BP; Boulad F; Bueso-Ramos C; Burroughs L; Castillo P; Connelly J; Davies SM; DiNardo CD; Hanif I; Ho RH; Karras N; Manalang M; McReynolds LJ; Nakano TA; Nalepa G; Norkin M; Oberley MJ; Orgel E; Pastore YD; Rosenthal J; Walkovich K; Larson J; Malsch M; Elghetany MT; Fleming MD; Shimamura A
Lancet Haematol; 2020 Mar; 7(3):e238-e246. PubMed ID: 31879230
[TBL] [Abstract][Full Text] [Related]
22. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.
Scott BL; Storer BE; Greene JE; Hackman RC; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2007 Mar; 13(3):345-54. PubMed ID: 17317588
[TBL] [Abstract][Full Text] [Related]
23. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
Wang H; Wang XQ; Xu XP; Lin GW
Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
[TBL] [Abstract][Full Text] [Related]
25. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
26. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
Lindsley RC; Saber W; Mar BG; Redd R; Wang T; Haagenson MD; Grauman PV; Hu ZH; Spellman SR; Lee SJ; Verneris MR; Hsu K; Fleischhauer K; Cutler C; Antin JH; Neuberg D; Ebert BL
N Engl J Med; 2017 Feb; 376(6):536-547. PubMed ID: 28177873
[TBL] [Abstract][Full Text] [Related]
28. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.
Gagelmann N; Eikema DJ; Stelljes M; Beelen D; de Wreede L; Mufti G; Knelange NS; Niederwieser D; Friis LS; Ehninger G; Nagler A; Yakoub-Agha I; Meijer E; Ljungman P; Maertens J; Kanz L; Lopez-Corral L; Brecht A; Craddock C; Finke J; Cornelissen JJ; Bernasconi P; Chevallier P; Sierra J; Robin M; Kröger N
Haematologica; 2019 May; 104(5):929-936. PubMed ID: 30655377
[TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.
Jain AG; Zhang L; Bennett JM; Komrokji R
Ann Lab Med; 2022 May; 42(3):299-305. PubMed ID: 34907099
[TBL] [Abstract][Full Text] [Related]
30. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.
Nazha A; Komrokji R; Meggendorfer M; Jia X; Radakovich N; Shreve J; Hilton CB; Nagata Y; Hamilton BK; Mukherjee S; Al Ali N; Walter W; Hutter S; Padron E; Sallman D; Kuzmanovic T; Kerr C; Adema V; Steensma DP; Dezern A; Roboz G; Garcia-Manero G; Erba H; Haferlach C; Maciejewski JP; Haferlach T; Sekeres MA
J Clin Oncol; 2021 Nov; 39(33):3737-3746. PubMed ID: 34406850
[TBL] [Abstract][Full Text] [Related]
31. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes.
Buesche G; Teoman H; Wilczak W; Ganser A; Hecker H; Wilkens L; Göhring G; Schlegelberger B; Bock O; Georgii A; Kreipe H
Leukemia; 2008 Feb; 22(2):313-22. PubMed ID: 18033321
[TBL] [Abstract][Full Text] [Related]
32. International scoring system for evaluating prognosis in myelodysplastic syndromes.
Greenberg P; Cox C; LeBeau MM; Fenaux P; Morel P; Sanz G; Sanz M; Vallespi T; Hamblin T; Oscier D; Ohyashiki K; Toyama K; Aul C; Mufti G; Bennett J
Blood; 1997 Mar; 89(6):2079-88. PubMed ID: 9058730
[TBL] [Abstract][Full Text] [Related]
33. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
34. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.
Schemenau J; Baldus S; Anlauf M; Reinecke P; Braunstein S; Blum S; Nachtkamp K; Neukirchen J; Strup C; Aul C; Haas R; Gattermann N; Germing U
Eur J Haematol; 2015 Sep; 95(3):181-9. PubMed ID: 25600827
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment.
Marques FK; Sabino AP
Biomed Pharmacother; 2022 Dec; 156():113905. PubMed ID: 36306593
[TBL] [Abstract][Full Text] [Related]
36. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
37. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
[TBL] [Abstract][Full Text] [Related]
38. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
39. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
Schanz J; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Tuechler H; Valent P; Hildebrandt B; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Kantarjian H; Germing U; Haase D; Estey E
J Clin Oncol; 2011 May; 29(15):1963-70. PubMed ID: 21519021
[TBL] [Abstract][Full Text] [Related]
40. IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
Wang N; Wang F; Shan N; Sui X; Xu H
Acta Haematol; 2017; 138(3):143-151. PubMed ID: 28873367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
